Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021

Rhea-AI Summary

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a Webcast to discuss its third quarter 2021 update and financial results on November 9 at 4:30 p.m. ET. Participants can register via a provided link to receive a confirmation email with Webcast details. A replay will be accessible from 7:30 p.m. ET on the same day until December 9. Acorda develops therapies for neurological disorders, including INBRIJA® for Parkinson's and AMPYRA® for multiple sclerosis. The press release also outlines potential risks affecting the company's market position and product sales.

Positive

• Webcast scheduled for November 9 to discuss Q3 2021 financial results and updates.
• Acorda's products focus on neurological disorders, targeting significant therapeutic markets.

Negative

• Risks associated with product marketing and potential impact from COVID-19 on business operations.
• Increased competition and loss of revenues in the U.S. market from generic versions of AMPYRA following patent expiration.

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a Webcast in conjunction with its third quarter 2021 update and financial results on Tuesday, November 9, at 4:30 p.m. ET.

To participate in the Webcast, please use the following pre-registration link:

• https://event.on24.com/wcc/r/3406044/9A2EE0FA8D73C4F1D09DB360AE69E236

Once you have registered, you will receive a confirmation email with Webcast details. You will receive an email 2 hours prior to the start of the call with the link to join. The presentation will be available in the Investors section of www.acorda.com.

A replay of the audio portion will be available from 7:30 p.m. ET on November 9, 2021 until 11:59 p.m. ET on December 9, 2021. To access the replay, please dial (866) 813 9403 (domestic) or +44 204 525 0658 (international); access code 602929. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking Statements

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market AMPYRA, INBRIJA or any other products under development; the COVID-19 pandemic, including related restrictions on in-person interactions and travel, and the potential for the illness and quarantines to affect our employees or consultants or those that work for other companies we rely upon, could have a material adverse effect on our business operations or product sales; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures; risks associated with the trading of our common stock and our reverse stock split; risks related to our corporate restructurings, including our ability to outsource certain operations, realize the expected cost savings, and maintain the workforce needed for continued operations; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA to meet market demand; our reliance on third-party manufacturers for the production of commercial supplies of AMPYRA and INBRIJA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA outside the U.S.; competition for INBRIJA and AMPYRA, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of AMPYRA (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class-action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third-party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005536/en/

Tierney Saccavino

(914) 326-5104

tsaccavino@acorda.com

Source: Acorda Therapeutics, Inc.

FAQ

When is Acorda Therapeutics' Q3 2021 financial results Webcast?

The Webcast is scheduled for November 9, 2021, at 4:30 p.m. ET.

How can I access the replay of the Acorda Therapeutics Q3 Webcast?

The replay will be available from 7:30 p.m. ET on November 9 until 11:59 p.m. ET on December 9.

What products does Acorda Therapeutics develop?

Acorda develops therapies for neurological disorders, including INBRIJA® for Parkinson’s disease and AMPYRA® for multiple sclerosis.

What risks did Acorda Therapeutics mention in their press release?

The release outlines risks related to product marketing, COVID-19 impact, and competition from generics.